Granted Patent
B2
US 12,396,945 · App. 17/648,841 · Granted Aug 26, 2025
Soft chewable pharmaceutical products
Inventors:
Susi Alteheld (Bad Kreuznach, DE); Stefan Fuchs (Essenheim, DE); Carina Hang (Grolsheim, DE); Jürgen Lutz (Wiesbaden, DE)
Assignee:
Intervet Inc.
A61K9/0056A61K9/145A61K9/1617A61K9/2013A61K9/282A61K9/4858A61K9/5015A61K9/5123A61K31/35A61K31/365A61K31/42A61K31/422A61K31/7048A61K45/06A61K47/10A61K47/12A61K47/16A61K47/18A61K47/20A61K47/22A61K47/26A61K47/36A61K47/38A61K47/42A61K47/44A61P33/00A61P33/14A61P43/00
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A soft chewable pharmaceutical product for delivery of a pharmaceutically acceptable active ingredient to an animal comprising pamoic acid or a pharmaceutically acceptable salt and a process for the manufacture of such soft chewable pharmaceutical product.
Claims (27)
1. A soft chewable veterinary pharmaceutical product comprising as ingredients,
a) one or more active pharmaceutical ingredients,
b) between 2.0 and 5.0% w/w of sodium pamoate,
c) between 5-30% w/w PEG as a forming agent with molecular weight higher than 600,
d) between 7.5% to about 40% of a liquid component comprising an oil and glycerol, and
wherein the soft chewable veterinary pharmaceutical product is processable on a forming equipment.
2. The product according to claim 1 , additionally comprising
a starch filler,
a stabilizer component,
a flavoring component, and
a sugar component.
3. The product according to claim 1 , wherein the active pharmaceutical ingredient is 4-[5-(3,5-Dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-y1]-2-methyl-N-[(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-benzamide.
4. The product according to claim 1 , wherein more than one active pharmaceutical ingredient is present.
5. The product according to claim 4 wherein the combination of active pharmaceutical ingredients comprises one or more antiparasitics.
6. A process for the manufacture of a product according to claim 1 comprising the steps of
a) mixing the ingredients into a dough,
b) filling a mold with dough, and
c) removing the dough from the mold,
wherein in the mixing step a) the sodium pamoate is mixed with the other ingredients.
7. The process of claim 6 , wherein the lubricity of a product is increased when filling the mold with dough or when removing the dough from the mold or both.
8. A method of controlling a parasitic insect, acarid or nematode infestation of an animal comprising administering to the animal the soft chewable veterinary pharmaceutical product of claim 1 wherein the one or more active pharmaceutical ingredient is
4-[5-(3,5-Dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-2-methyl-N-[(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-benzamide.
9. The process according to claim 6 , wherein for the manufacturing a forming machine is used.
10. The product according to claim 3 , wherein more than one active pharmaceutical ingredient is present.
11. The product according to claim 10 , wherein the combination of active pharmaceutical ingredients comprises one or more antiparasitics.
12. The product according to claim 2 , wherein the stabilizer is BHT.
13. The soft chewable veterinary pharmaceutical product according to claim 1 , wherein the product comprises between 10-20% w/w PEG.
Assignments (2)
CHANGE OF ADDRESS
Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 25, 2022
From: ALTEHELD, SUSI; FUCHS, STEFAN; HANG, CARINA; LUTZ, JURGEN
To: INTERVET INC.
Reel/Frame 058759/0024 →
Priority Claims (1)
EP 121631980
· Apr 4, 2012
· regional
Continuity (5)
Continuation
14390040
Provisional Application
61782434
· Mar 14, 2013
References Cited (260)
US 3486186A
· Richards et al.
· 1969
[cited by applicant]
US 3887964A
· Richards
· 1975
[cited by applicant]
US 3952478A
· Richards et al.
· 1976
[cited by applicant]
US 4054967A
· Sandberg et al.
· 1977
[cited by applicant]
US 4097961A
· Richards
· 1978
[cited by applicant]
US 4182003A
· Lamartino et al.
· 1980
[cited by applicant]
US 4284652A
· Christensen
· 1981
[cited by applicant]
US 4327076A
· Puglia et al.
· 1982
[cited by applicant]
US 4334339A
· Holly
· 1982
[cited by applicant]
US 4338702A
· Holly
· 1982
[cited by applicant]
US 4343068A
· Holly
· 1982
[cited by applicant]
US 4356595A
· Sandberg et al.
· 1982
[cited by applicant]
US 4372008A
· Sandberg
· 1983
[cited by applicant]
US 4393085A
· Spradlin et al.
· 1983
[cited by applicant]
US 4535505A
· Holly et al.
· 1985
[cited by applicant]
US 4597135A
· Holly et al.
· 1986
[cited by applicant]
US 4608731A
· Holly
· 1986
[cited by applicant]
US 4609543A
· Morris et al.
· 1986
[cited by applicant]
US 4622717A
· Bollinger
· 1986
[cited by applicant]
US 4697308A
· Sandberg
· 1987
[cited by applicant]
US 4768941A
· Wagner
· 1988
[cited by applicant]
US 4780931A
· Powers et al.
· 1988
[cited by applicant]
US 4818446A
· Schreiber et al.
· 1989
[cited by applicant]
US 4821376A
· Sandberg
· 1989
[cited by applicant]
US 4872241A
· Lindee
· 1989
[cited by applicant]
US 4935243A
· Borkan et al.
· 1990
[cited by applicant]
US 4975039A
· Dare et al.
· 1990
[cited by applicant]
US 4996743A
· Janssen
· 1991
[cited by applicant]
US 4997671A
· Spanier
· 1991
[cited by applicant]
US 5021025A
· Wagner
· 1991
[cited by applicant]
US 5022888A
· Lindee
· 1991
[cited by applicant]
US 5236730A
· Yamada et al.
· 1993
[cited by applicant]
US 5262167A
· Vegesna et al.
· 1993
[cited by applicant]
US 5380535A
· Geyer et al.
· 1995
[cited by applicant]
US 5439924A
· Miller et al.
· 1995
[cited by applicant]
US 5578336A
· Monte
· 1996
[cited by applicant]
US 5637313A
· Chau et al.
· 1997
[cited by applicant]
US 5655436A
· Soper
· 1997
[cited by applicant]
US 5753255A
· Chavkin et al.
· 1998
[cited by applicant]
US 5824336A
· Jans et al.
· 1998
[cited by applicant]
US 5827565A
· Axelrod
· 1998
[cited by applicant]
US 5958445A
· Humber et al.
· 1999
[cited by applicant]
US 5980228A
· Soper
· 1999
[cited by applicant]
US 6060078A
· Lee
· 2000
[cited by applicant]
US 6086940A
· Axelrod
· 2000
[cited by applicant]
US 6093427A
· Axelrod
· 2000
[cited by applicant]
US 6093441A
· Axelrod
· 2000
[cited by applicant]
US 6110521A
· Axelrod
· 2000
[cited by applicant]
US 6159516A
· Axelrod et al.
· 2000
[cited by applicant]
US 6270790B1
· Robinson et al.
· 2001
[cited by applicant]
US 6387381B2
· Christensen
· 2002
[cited by applicant]
US 6500463B1
· van Lengerich
· 2002
[cited by applicant]
US 7348027B2
· Rose et al.
· 2008
[cited by applicant]
US 7662972B2
· Mita et al.
· 2010
[cited by applicant]
US 7947715B2
· Mita et al.
· 2011
[cited by applicant]
US 7951828B1
· Mita et al.
· 2011
[cited by applicant]
US 7955632B2
· Paulsen et al.
· 2011
[cited by applicant]
US 8022089B2
· Mita et al.
· 2011
[cited by applicant]
US 8138213B2
· Mita et al.
· 2012
[cited by applicant]
US 8426460B2
· Meng
· 2013
[cited by applicant]
US 8492311B2
· Mita et al.
· 2013
[cited by applicant]
US 8796464B2
· Moriyama et al.
· 2014
[cited by applicant]
US 9259417B2
· Soll
· 2016
[cited by examiner]
US 20010036464A1
· Christensen
· 2001
[cited by applicant]
US 20010055598A1
· Kalbe et al.
· 2001
[cited by applicant]
US 20030007958A1
· Chen
· 2003
[cited by applicant]
US 20040037869A1
· Cleverly et al.
· 2004
[cited by applicant]
US 20040234579A1
· Finke
· 2004
[cited by applicant]
US 20050226908A1
· Huron et al.
· 2005
[cited by applicant]
US 20060141009A1
· Huron et al.
· 2006
[cited by applicant]
US 20080293645A1
· Schneider
· 2008
[cited by applicant]
US 20090281059A1
· Falotico et al.
· 2009
[cited by applicant]
US 20100249191A1
· Coqueron et al.
· 2010
[cited by applicant]
US 20110059988A1
· Heckeroth
· 2011
[cited by examiner]
US 20120030841A1
· Koerber et al.
· 2012
[cited by applicant]
AU 2010206029B2
· 2012
[cited by applicant]
CN 1930136A
· 2007
[cited by applicant]
CN 101190223A
· 2008
[cited by applicant]
CN 101743000A
· 2010
[cited by applicant]
CN 101765592A
· 2010
[cited by applicant]
CN 101778566A
· 2010
[cited by applicant]
CN 101919857
· 2010
[cited by applicant]
CN 101919857A
· 2010
[cited by applicant]
CN 102088857A
· 2011
[cited by applicant]
CN 102256971A
· 2011
[cited by applicant]
CN 101522672B
· 2012
[cited by applicant]
CN 101909605B
· 2013
[cited by applicant]
CN 101652354B
· 2014
[cited by applicant]
CN 102088856B
· 2015
[cited by applicant]
EP 0075443A2
· 1983
[cited by applicant]
EP 0273001A2
· 1988
[cited by applicant]
EP 0492235A1
· 1992
[cited by applicant]
EP 1023841A1
· 2000
[cited by applicant]
EP 1247456A2
· 2002
[cited by applicant]
EP 1688149A1
· 2006
[cited by applicant]
EP 1731512A1
· 2006
[cited by applicant]
GB 819681
· 1959
[cited by applicant]
GB 2300103A
· 1996
[cited by applicant]
KR 20100057066A
· 2010
[cited by applicant]
NZ 286545A
· 1998
[cited by applicant]
RU 2356534C2
· 2009
[cited by applicant]
WO 1994025460
· 1994
[cited by applicant]
WO 1999048372A1
· 1999
[cited by applicant]
WO WO200027849
· 2000
[cited by examiner]
WO 2001037667A1
· 2001
[cited by applicant]
WO 0200603A1
· 2002
[cited by applicant]
WO 2002060255A2
· 2002
[cited by applicant]
WO 2002094288A1
· 2002
[cited by applicant]
WO 2003030653A2
· 2003
[cited by applicant]
WO 2004014143A1
· 2004
[cited by applicant]
WO 2004017970
· 2004
[cited by applicant]
WO 2005013714A1
· 2005
[cited by applicant]
WO 2005016261
· 2005
[cited by applicant]
WO 2005016356A1
· 2005
[cited by applicant]
WO 2005062782A2
· 2005
[cited by applicant]
WO 2005075454
· 2005
[cited by applicant]
WO 2005085216A1
· 2005
[cited by applicant]
WO 2005099453A1
· 2005
[cited by applicant]
WO 2005099692A1
· 2005
[cited by applicant]
WO 2006005578A2
· 2006
[cited by applicant]
WO 2007067582A2
· 2007
[cited by applicant]
WO 2007070606A2
· 2007
[cited by applicant]
WO 2007075459A2
· 2007
[cited by applicant]
WO 2007079162A1
· 2007
[cited by applicant]
WO 2007123855A2
· 2007
[cited by applicant]
WO 2008030469A2
· 2008
[cited by applicant]
WO 2008134819A1
· 2008
[cited by applicant]
WO 2008136791A1
· 2008
[cited by applicant]
WO 2008144275A1
· 2008
[cited by applicant]
WO 2008148027A1
· 2008
[cited by applicant]
WO 2008154528A2
· 2008
[cited by applicant]
WO 2009002809A2
· 2008
[cited by applicant]
WO 2009003075A1
· 2008
[cited by applicant]
WO 2009024541A2
· 2009
[cited by applicant]
WO 2009064859A1
· 2009
[cited by applicant]
WO 2009080250A2
· 2009
[cited by applicant]
WO 2010003923A1
· 2010
[cited by applicant]
WO 2010056999A1
· 2010
[cited by applicant]
WO 2010070068A2
· 2010
[cited by applicant]
WO 2010079077A1
· 2010
[cited by applicant]
WO 2010084067A2
· 2010
[cited by applicant]
WO 2011011235
· 2011
[cited by applicant]
WO 2011067272A1
· 2011
[cited by applicant]
WO 2011075591A1
· 2011
[cited by applicant]
WO 2011092287A1
· 2011
[cited by applicant]
WO 2011104087A1
· 2011
[cited by applicant]
WO 2011124998A1
· 2011
[cited by applicant]
WO 2011149749A1
· 2011
[cited by applicant]
WO 2011154433A2
· 2011
[cited by applicant]
WO 2011154434A2
· 2011
[cited by applicant]
WO 2011154494A2
· 2011
[cited by applicant]
WO 2011157733A2
· 2011
[cited by applicant]
WO 2012003231A1
· 2012
[cited by applicant]
WO 2012007426A1
· 2012
[cited by applicant]
WO 2012038851A1
· 2012
[cited by applicant]
WO 2012049156A1
· 2012
[cited by applicant]
WO WO2012049156
· 2012
[cited by examiner]
WO 2013039948A1
· 2013
[cited by applicant]
WO 2014079825A1
· 2014
[cited by applicant]
U.S. Appl. No. 16/296,490, filed Mar. 8, 2019.
[cited by applicant]
U.S. Appl. No. 15/613,848, filed Jun. 5, 2017.
[cited by applicant]
U.S. Appl. No. 15/433,901, filed Feb. 15, 2017.
[cited by applicant]
U.S. Appl. No. 15/390,244, filed Dec. 23, 2016.
[cited by applicant]
Alturix Limited, Slow Sodium, Summary of Product Characteristics, 2021, 1-3, N/A.
[cited by applicant]
Hospira, Sodium Acetate, NDA 18893/S-025, 2010, 4-7, N/A.
[cited by applicant]
Al-Juhaimi, Fahad et al., Effects of different levels of Moringa (Moringa oleifera) seed flour on quality attributes of beef burgers, CyTA—Journal of Food, 2015, 1-11, N/A.
[cited by applicant]
Aljaberi, Ahmad et al., Understanding and optimizing the dual excipient functionality of sodium lauryl sulfate in tablet formulation of poorly water soluble drug: wetting and lubrication, Pharmaceutical Development and …
[cited by applicant]
Beugnet, Frederic et al., Comparative efficacy of two oral treatments for dogs containing either afoxolaner or luralaner against Rhipicephalus sanguineus sensu lato and Dermacentor reticulatus, Veterinary Parasitology, …
[cited by applicant]
Beugnet, Frederic et al., Comparative speed of efficacy against Ctenocephalides felis oftwo oral treatments for dogs containing either afoxolaner orfluralaner, Veterinary Parasitology, 2015, 297-301, 207.
[cited by applicant]
Beugnet, Frédéric et al., Parasites of domestic owned cats in Europe: co-infestations and risk factors, Parasites & Vectors, 2014, 1-13, 7:291.
[cited by applicant]
Brookfield Ametek, Texture Analysis Application Note: Cooked Hamburger Patties, Testing the Limited in texture analysis, 2019, 1-2, N/A.
[cited by applicant]
Chinese Patent Application for Invention No. 201810385736.3, in the name of Intervet International B.V., reporting letter regarding Fourth Office Action, dated Dec. 10, 2021 (26 pages).
[cited by applicant]
Clark, Jn et al., Efficacy of ivermectin and pyrantel pamoate combined in a chewable formulation against heartworm, hookworm, and ascarid infections in dogs, Am J Vet Res, 1992, pp. 517-520, 53 (4).
[cited by applicant]
Clark, Jn et al., Evaluation of a beef-based chewable formulation of pyrantel pamoate against induced and natural Infections of hookworms and ascarids in dogs, Veterinary Parasitology, 1991, pp. 127-133, 40.
[cited by applicant]
Colorcon Company, Starch 1500 Partially Pregelatinized Maise Starch, Technical Information Brochure, 2008, 1-6, Brochure.
[cited by applicant]
Committee for Veterinary Medicinal Products, “Polyethylene Glycol Stearates and Polyethylene Glycol 15 Hydroxystearate”, EMEA/MRL/392/98-FINAL-REV.1, 2003.
[cited by applicant]
Decision of Opposition Division against patent EP2833866 in the name of Intervet International B.V. dated Jul. 14, 2021, 30 pages.
[cited by applicant]
Declaration-Bd.R. 203(b), Interference 106,900, U.S. Appl. No. 15/634,924, dated Dec. 26, 2017, 8 pages.
[cited by applicant]
Declaration of Brenda Valee Colon, in the matter of EP2833866, EP application No. 13715654.3, dated Sep. 4, 2020, 1 page.
[cited by applicant]
Declaration Under 37 C.F.R. § 1.132 Of Keith Freehauf, U.S. Appl. No. 14/082,813, dated Jul. 26, 2016, 7 pages.
[cited by applicant]
Declaration Under 37 C.F.R. § 1.132 of Niki Waldron, U.S. Appl. No. 14/082,813, dated Dec. 17, 2015, 8 pages.
[cited by applicant]
Drug Bank, Pryantel, 2015, (updated Aug. 10, 2020) Accession No. DB11156, pp. 1-22.
[cited by applicant]
English language translation of letter from opponent 1 (Virbac) against patent EP2833866 in the name of Intervet International B.V. dated Mar. 26, 2021, 20 pages.
[cited by applicant]
English language translation of letter from opponent 1 (Virbac) against patent EP2833866 in the name of Intervet International B.V. dated May 6, 2021, 14 pages.
[cited by applicant]
English language translation of Letter from opponent 1 (Virbac) against patent EP2833866 in the name of Intervet International B.V. dated Sep. 10, 2020, 50 pages.
[cited by applicant]
English language translation of letter from opponent 2 (CEVA) against patent EP2833866 in the name of Intervet International B.V. dated Sep. 10, 2020, 11 pages.
[cited by applicant]
European Medicines Agency EPAR Product Information for Bravecto, published 26, 2014, 20 pages.
[cited by applicant]
European Medicines Agency, Science Medicines Health, CVMP assessment report for Bravecto, Committee for Medicinal Products for Veterinary Use (CVMP), 2013, 22 pages, N/A.
[cited by applicant]
European Search Report for 12163198.0, mailed on Aug. 16, 2012.
[cited by applicant]
Gates, Mc, et al., Factors influencing heartworm, flea, and tick preventive use in patients presenting to a veterinary teaching hospital, Preventive Veterinary Medicine, 2010, pp. 1-16, 93(2-3).
[cited by applicant]
Intervet, Inc., Corrected Freedom of Information Summary, NADA 141-426, 2014, 1-40, N/A.
[cited by applicant]
Kilp, S et al, Pharmacokinetics of fluralaner in dogs following a single oral or intravenous administration, Parasites & Vectors, 2014, 1-5, 7:85.
[cited by applicant]
Letter from opponent 1 (Virbac) against patent EP2833866 in the name of Intervet International B.V. dated Mar. 26, 2021, 13 pages.
[cited by applicant]
Letter from opponent 1 (Virbac) against patent EP2833866 in the name of Intervet International B.V. dated May 6, 2021, 11 pages.
[cited by applicant]
Letter from opponent 1 (Virbac) against patent EP2833866 in the name of Intervet International B.V. dated Sep. 10, 2020, 34 pages.
[cited by applicant]
Letter from opponent 2 (CEVA) against patent EP2833866 in the name of Intervet International B.V. dated Sep. 10, 2020, 8 pages.
[cited by applicant]
Meadows, Cheyney et al., A randomized, blinded, controlled USA field study to assess the use of fluralaner tablets in controlling canine flea infestations, Parasites & Vectors, 2014, 1-8, 7:375.
[cited by applicant]
Neubig, RR, Mind Your Salts: When the Inactive Constituent Isn't, Molecular Pharmacology, Jul. 22, 2010, pp. 558-559, vol. 78, No. 4,, EP.
[cited by applicant]
Office Action mailed on Jun. 7, 2016 for U.S. Appl. No. 14/390,040, 18 pages.
[cited by applicant]
Opposition against European Patent EP 2833866 (Application No. 13715654.3), Intervet International BV, Reply to Summons for Oral Proceedings before the Opposition Division, dated Mar. 25, 2021, 92 pages.
[cited by applicant]
Opposition Notice in the name of Ceva Sante Animale against patent EP2833866 in the name of Intervet International B.V. dated Aug. 27, 2019, 19 pages.
[cited by applicant]
Opposition Notice in the name of VIRBAC against patent EP2833866 in the name of Intervet International B.V. dated Aug. 26, 2019, 30 pages.
[cited by applicant]
Ozoe, et al, The antiparasitic isoxazoline A1443 is a potent blocker of insect ligand-gated chloride channels, Biochemical and Biophysical Research Communications, 2010, pp. 744-749, vol. 391.
[cited by applicant]
PCT International Search Report for corresponding PCT/EP2013/056987, mailed on Aug. 12, 2013, 5 Pages.
[cited by applicant]
Pharmtech.com, Advancing Development and Manufacturing, “Salt Selection in Drug Development”, vol. 32, Issue 3, Mar. 2, 2008, 13 pages.
[cited by applicant]
Plerion 10 Packaging and Package Leaflet, Intervet UK Ltd. & Intervet Ireland Ltd. (2009). 6 pages.
[cited by applicant]
Plerion 5 Packaging and Package Leaflet, Intervet UK Ltd. & Intervet Ireland Ltd. (2009), 4 pages.
[cited by applicant]
Plumb, DC, Pyrantel pamoate, Veterinary Drug Handbook, 2011, pp. 880-882, 7th Edition.
[cited by applicant]
Preliminary opinion of Opposition Division against patent EP2833866 in the name of Intervet International B.V. dated Feb. 11, 2020, 14 pages.
[cited by applicant]
Remington: The Science and Practice of Pharmacy 20th Edition, 2000, p. 876.
[cited by applicant]
Remington: The Science and Practice of Pharmacy, 20th edition, Pyrantel Pamoate, p. 1564, 2000, 3 pages.
[cited by applicant]
Response to Office Action for U.S. Appl. No. 14/390,040, dated Sep. 29, 2016, 12 pages.
[cited by applicant]
Rohdich, N et al, A randomized, blinded, controlled and multi-centered field study comparing the efficacy and safety of Bravecto™ (fluralaner) against Frontline™ (fipronil) in flea-and tick-infested dogs, Parasites & Ve…
[cited by applicant]
Second Declaration of James E. Polli, Ph.D., Exhibit 2060, Interference 106,900, U.S. Appl. No. 15/634,924, filed Jun. 26, 2018, 70 pages.
[cited by applicant]
Sittig, Marshall et al., Pharmaceutical Manufacturing Encyclopedia, Changchun Publishing House, 1992, 771, N/A.
[cited by applicant]
Stahl, Ph et al., Pamoic Acid, Handbook of Pharmaceutical Salts, 2008, p. 301 (3 pages total).
[cited by applicant]
Summary of Product Characteristics, Plerion Chewable Tablets for Dogs from 2.5 kg, as published by Veterinary Medicines Directorate, UK (2014; initially authorized in 2009), 6 pages.
[cited by applicant]
Summary of Product Characteristics, Plerion Chewable Tablets for Dogs from 5 kg, as published by Veterinary Medicines Directorate, UK (2014; initially authorized in 2009), 6 pages.
[cited by applicant]
Taenzler, Janina, Onset of activity of fluralaner (BRAVECTO™) against Ctenocephalides felis on dogs, Parasites & Vectors, 2014, 1-4, 7:567.
[cited by applicant]
Translation of the opposition in the name of Ceva Sante Animale against patent EP2833866 in the name of Intervet International B.V. dated 2019, 22 pages.
[cited by applicant]
Translation of the opposition in the name of VIRBAC against patent EP2833866 in the name of Intervet International B. V. dated 2019, 33 pages.
[cited by applicant]
U.S. Appl. No. 61/728,379, filed Nov. 20, 2012, titled Manufacturing of Semi-Plastic Pharmaceutical Dosage Units, No. of pp. 36.
[cited by applicant]
Vercruysse, et al., Pharmacokinetics of Anthelmintics, 2014, pp. 1-4, MSD Manual-Veterinary Manual.
[cited by applicant]
Walther, Feli M. et al., Safety of concurrent treatment of dogs with fluralaner (Bravecto™) and milbemycin oxime—praziquantel, Parasites & Vectors, 2014, 1-3, 7:481.
[cited by applicant]
Walther, Feli M. et al., Safety of fluralaner chewable tablets (BravectoTM), a novel systemic antiparasitic drug, in dogs after oral administration, Parasites & Vectors, 2014, 1-7, 7:87.
[cited by applicant]
Walther, Feli M. et al., Safety of fluralaner, a novel systemic antiparasitic drug, in MDR1(-/-) Collies after oral administration, Parasites & Vectors, 2014, 1-3, 7:86.
[cited by applicant]
Walther, Feli M. et al., Safety of the concurrent treatment of dogs with Bravecto™ (fluralaner) and Scalibor™ protectorband (deltamethrin), Parasites & Vectors, 2014, 1-2, 7:105.
[cited by applicant]
Walther, FM., et al., The effect of food on the pharmacokinetics, Parasites & Vectors, 2014, pp. 1-4, 7:84, Elsevier.
[cited by applicant]
Wengenmayer, Christina et al., The speed of kill of fluralaner (Bravecto™) against Ixodes ricinus ticks on dogs, Parasites & Vectors, 2014, 1-5, 7:525.
[cited by applicant]
Williams, Heike et al., Fluralaner, a novel isoxazoline, prevents flea (Ctenocephalides felis) reproduction in vitro and in a simulated home environment, Parasites & Vectors, 2014, 1-6, 7:275.
[cited by applicant]
Yu, X et al., The effectiveness of two anthelmintics vermox (mebendazole) and povan (pyrvinium pamoate), on thelastomatid nematodes (nematoda: oxyuroidea) of the cockroach, gromphadorhina portentosa, Ohio Journal of Sci…
[cited by applicant]
Zhao ,et al, Targeting of the Orphan receptor GPR35 by Pamoic Acid, Molecular Pharmacology, 2010, pp. 560-568, vol. 78 , No. 4.
[cited by applicant]